Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus

What Was Tested

Researchers studied Ghrelin and Apelin in this randomized controlled trial publication.

The researchers aimed to assess the differential effects of either rosiglitazone or metformin monotherapy on the aforementioned adipocytokines in patients with type 2 diabetes mellitus (T2DM).

Why It Was Studied

Visfatin, ghrelin, and apelin are the most recently identified adipocytokines; but their response to insulin-sensitizing agents is poorly clarified.

Who Took Part

The abstract describes 30 men taking part.

PubMed indexes the participants as middle-aged adults and older adults, both men and women.

Anthropometric parameters, glycemic and lipid profile, high-sensitivity CRP (hs-CRP), insulin resistance (homeostasis model assessment of insulin resistance index [HOMA-IR]), visfatin, ghrelin, and apelin were assessed at baseline and after 14 weeks of therapy.

How the Study Was Run

In design terms this was a randomized study.

Because people in this Ghrelin study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The methods mention a period of 14 weeks.

What Was Measured

The subject headings attached to it are Adipokines, Apelin, C-Reactive Protein, Diabetes Mellitus, Type 2, Ghrelin, Hypoglycemic Agents and Intercellular Signaling Peptides and Proteins.

What This Means in Plain Language

The paper is a randomized study of Ghrelin and Apelin in 30 men over 14 weeks.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2010 (Metabolism: clinical and experimental), a journal based in United States.

More context: the Ghrelin compound page and the Apelin compound page, all human trials.